Investor Relations

Proven technology. Expanding markets. Growing value.

View reports

98%

of sufferers untreated — our target market

$60B

global varicose vein market

55+

patents in 20 countries

3,200+

procedures in 12 countries

85%

gross margin achieved

VVT Med Inc.

VVT Med Inc. (TSXV:VVTM) develops, manufactures, and markets minimally invasive, non-thermal solutions for venous disease treatments. Its devices, ScleroSafe™ and V-Block™, are commercially available worldwide. VVT's proprietary dual-mode technology delivers safe, efficient, and anesthesia-free procedures. With global adoption accelerating, VVT is positioned for growth in the expanding non-thermal vein care market.

Read latest news Financial Reports

A vast, untapped market

40M

Americans suffer from symptomatic varicose veins

Patients seek treatment

<3%

Are actually treated

$1.3B

Spent annually in the US

$60B

Total addressable market

Source: Alzheimer's Association 2020, ACS Cancer facts and figures 2020, Virnai SS. Circulation 2020;141:e139–e569, CDC National Diabetes Statistic report 2020, Yost CLI Suppl 2016 THE SAGE GROUP and Yost ML Chronic Venous Disease THE SAGE

Did You Know?

Did you know?

Venous Insufficiency

is one of medicine's most underreported crises.

11 facts that will change how you see vein disease.

01 Brazil · Labor impact

27M

workdays lost to vein disease in just 10 years

Between 2005–2014, Brazil's social security system recorded over 27 million lost workdays due to chronic venous disease. The average worker was disabled for 55 days per episode, and social security costs grew 3.5× over the decade.

Source: BMC Public Health, 2020 · Brazilian Social Security System database

02 Global · Economics

of Western healthcare budgets consumed by vein disease

Varicose veins and venous leg ulcers together account for up to 2% of the entire annual healthcare spend across Western countries. In Europe and North America combined, the total burden exceeds $14 billion every year, before out-of-pocket costs.

Source: Journal of Vascular Surgery, 2023 · Bergan et al.

03 United States · Cost

$3B

spent annually on venous ulcer care in the US alone

Over 25 million Americans have chronic venous insufficiency, with 6 million suffering advanced disease. Venous ulcer care alone costs $3 billion per year, and CVI causes 2 million lost workdays annually in the US.

Source: PMC / Journal of Vascular Surgery · Circulation, American Heart Association

04 Workforce · Hidden cost

1 in 8

workers with venous ulcers are forced into early retirement

More than 12% of workers with venous ulcers retire early as a direct result of their condition. This is not a cosmetic problem. It is a career-ending disability for over one in eight patients who reach advanced stage disease.

Source: Circulation / American Heart Association · CVI Review

05 Pregnancy · Overlooked risk

“Up to 80% of pregnant women develop venous insufficiency.”

Most consider it cosmetic. The data says otherwise.

CVI occurs in up to 80% of pregnancies, while 7 in every 1,000 expectant mothers face venous thromboembolism or pulmonary embolism, a leading cause of pregnancy-related death in the US.

Source: Society for Vascular Surgery · Journal of Vascular Surgery, Johns Hopkins, 2018

06 Middle East · Surprising prevalence

45.6%

of Saudi adults have chronic venous insufficiency

Contrary to assumptions, venous disease is not just a Western problem. Saudi Arabia reports a 45.6% CVI prevalence, higher than the UK or France. Prolonged standing, sedentary lifestyle, and hormonal factors push rates above 49% in women.

Source: Saudi Med J, PubMed 2005 · Al-Shammeri et al.

07 India · Scale of the problem

37%

of India's population estimated to be affected

Studies of Indian populations find varicose veins in up to 46.7% of women and 27.8% of men in studied regions. One estimate places overall Indian prevalence at 37.25%, yet the condition receives minimal public health attention.

Source: Int. Journal of Research in Medical Sciences, 2016 · Agarwal et al.

08 United Kingdom · NHS burden

£941M

per year: what the NHS spends on venous leg ulcers

UK district nurses spend up to 80% of their time caring for leg ulcer patients. An unhealed venous ulcer costs the NHS 4.5× more than a healed one (£13,500 vs £3,000), yet most patients never receive intervention targeting the root cause.

Source: Molnlycke Wound Care Review · PubMed 2018

09 Treatment · Recurrence crisis

60–70%

of venous ulcers recur within 10 years

Venous leg ulcers account for 70% of all chronic leg ulcers, and 60–70% recur within a decade. The default treatment, compression bandaging, does not treat the underlying reflux. This is why the wound keeps coming back.

Source: Vascular Medicine, 2022 · Kolluri et al. / SAGE

10 Global · Lifetime risk

“The majority of adults will develop some form of venous disease in their lifetime.”

This is not rare. This is not niche. This is everyone.

A 2020 global meta-analysis found that 26% of people have spider veins, 19% raised varicose veins, 8% leg swelling, and 4% skin changes. Combined, most adults will experience at least one stage of venous disease before they die.

Source: ScienceInsights synthesis of 2020 global meta-analysis (32 studies, 6 continents)

11 Brazil · Inequality

68%

of Brazil's venous disease disability cases are women

Of the 429,000+ workers who received disability benefits in Brazil due to venous disease over a decade, 68% were women and 83% earned under twice the minimum wage. Vein disease disproportionately disables the most economically vulnerable.

Source: BMC Public Health, 2020 · Brazilian Social Security System

The treatment landscape is changing.

Non-thermal, non-tumescent technologies are emerging as the next standard of care, addressing root-cause reflux with same-day recovery.

Why VVT Med

FDA-Cleared NTNT Platform

The only non-thermal, non-tumescent technology with the broadest vein diameter coverage. No anesthesia required. Strategics are actively seeking proven NTNT solutions.

510(k) + CE + 18 more

Universal Vein Coverage

ScleroSafe™ and V-Block™ together treat the widest range of vein diameters on the market, from peripheral veins to highly dilated saphenous veins.

Dual-product platform

No Capital Expense for Clinics

Clinics can adopt ScleroSafe™ without purchasing capital equipment. Lower barrier to adoption accelerates market penetration and speeds revenue growth.

Consumable model

Proven M&A Precedent

$5.8B in recent strategic acquisitions in the space: Sapheon, Vascular Solutions, Varithena, Venclose. Major players including Medtronic and Boston Scientific are actively seeking NTNT solutions.

$5.8B M&A precedent

Signed deals across 14 countries

Distribution agreements in place with minimum purchase commitments across North America, Asia, and Europe.

United States — Distribution

Methapharm

$25M CAD

5-year exclusive distribution agreement with Methapharm, a Canadian company operating in the US market.

India

Leading National Distributor

$3.7M CAD

Distribution agreement with leading national distributor. Government reimbursement in progress.

South Korea

Distribution Agreement

$2.5M CAD

Procedure reimbursement granted. Distribution agreement in place with established vascular partner.

Italy

New Distribution Agreement

$2.3M CAD

First patients treated at Venice hospital. Expanding European commercial footprint through exclusive agreement.

Greece

General Chemical Products S.A.

€712K CAD

Five-year exclusive distribution agreement with minimum purchase commitments (~CAD$1.14M).

Dominican Republic

Antilles Medical

Exclusive

Trial Distribution and Evaluation Agreement with structured pathway toward a five-year partnership.

Canada

CHS (Canadian Hospital Specialties)

Exclusive

Five-year exclusive distribution agreement with CHS, reaching approximately 84% of Canadian customers within 48 hours, subject to Health Canada regulatory authorization.

Panama

Ebtec

Exclusive

12-month Trial Distribution and Evaluation Agreement with initial order of at least 10 ScleroSafe® Full Sets and a pathway toward a five-year partnership.

Also active in Macedonia · Israel · Poland · Germany · Portugal · Brazil · + recurring orders expanding

Clinical outcomes that speak for themselves

A prospective observational study of 30 patients (CEAP C2–C5) treated with ScleroSafe™ catheter-directed sclerotherapy. Immediate symptom relief in 80% of patients within 24 hours. Zero serious adverse events recorded.

Indian Journal of Vascular & Endovascular Surgery, Vol. 13, 2026 — Bhuiyan & Sheth

100%

Technical Success Rate

All treated cases

95%

Vein Occlusion at Day 30

Comparable to EVLA / RFA

Zero

DVT / Nerve Injury / Skin Necrosis

No serious adverse events